AlphaQuest’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

AlphaQuest’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,421	Closed	-$319K	–	2192
2025 Q1	$319K	Sell	2,421 -1,562	-39%	-$195K	0.03%	735
2024 Q4	$333K	Buy	3,983 +3,975	+49,688%	+$327K	0.04%	657
2024 Q3	$585	Buy	8 +1	+14%	+$75	﹤0.01%	1693
2024 Q2	$479	Sell	7 -721	-99%	-$50K	﹤0.01%	1419
2024 Q1	$50.4K	Buy	+728	New	+$50K	0.01%	935

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AlphaQuest's ITCI Position: Q2 2025 in Review

AlphaQuest sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,421 shares — an estimated $319K sold.

AlphaQuest first reported a position in ITCI in Q1 2024 and held it in 5 quarters. The position peaked at $333K in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

AlphaQuest reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
AlphaQuest sold 2,421 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $319K.
AlphaQuest first reported a position in Intra-Cellular Therapies Inc. in Q1 2024 and held it in 5 quarters.
AlphaQuest's Intra-Cellular Therapies Inc. position peaked at $333K in Q4 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on AlphaQuest's 13F filing for Q2 2025, filed 31 Jul 2025.